KELLY SPYCHALSKI: Open Payments
NPI 1790182368 · ADA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,007 in 29 payments from 17 companies in 2025. Trend: 2023 $1,413 · 2024 $928 · 2025 $1,007
Food & beverage: $1,007
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $284 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 4 | $117 |
| Genmab U.S., Inc. | 1 | $83 |
| GENZYME CORPORATION | 2 | $62 |
| Stemline Therapeutics Inc. | 2 | $51 |
| Sumitomo Pharma America, Inc. | 1 | $50 |
| Incyte Corporation | 2 | $33 |
| Merck Sharp & Dohme LLC | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $26 |
Products named: RYBREVANT, Epkinly, SARCLISA, Orserdu, ORGOVYX, TALVEY, KEYTRUDA, Enhertu.
Industry payments across OK — which companies pay providers there.
